~~<i id='DB45814879'><strike id='DB45814879'><tt id='DB45814879'><pre id='DB45814879'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：explore 2025-09-28 11:08:32 Page View：486

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Type 2 diabetes prevention programs work at large scale: study
Next article： What does generative AI mean for health care? We asked experts

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

A letter from the executive editor: STAT UnitedHealth investigation

MikeReddyforSTATIwanttobringyourattentiontoavitallyimportant investigation STAThaspublishedtoday.For

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Shingles, which affected Dianne Feinstein, is on the rise

PicturesofSenatorDianneFeinsteinrestbyacondolencebookatCityHallinSanFranciscoonFriday.BenjaminFanjoy